Canadian Cardiovascular Society Antiplatelet Guidelines USE OF ANTIPLATELET

In the PLATelet inhibition and patient Outcomes (PLATO) trial, tica- grelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with...

Uploaded by: Murkka Svensdottir
Filesize: 7 MB